Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial

Archives of Internal Medicine

Volumn 160, Issue 14, 2000, Pages 2185-2191

  McMahon, F Gilbert ^a   Fujioka, Ken ^b   Singh, Bramah N ^c   Mendel, Carl M ^d   Rowe, Everton ^d   Rolston, Kelly ^d   Johnson, Franklin ^d   Mooradian, Arshag D ^e  

^a General Clinical Research Center New Orleans   (United States)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ABBOTT LABORATORIES   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIBUTRAMINE; TRIACYLGLYCEROL; URIC ACID;

ADULT; ANTHROPOMETRY; ARTICLE; BACKACHE; BLOOD CHEMISTRY; CAUCASIAN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; OBESITY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SINUSITIS; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0034710218     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.14.2185     Document Type: Article

References (56)

1. Stunkard AJ. Current views on obesity. Am J Med. 1996;100:230-236.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-211.
3. Williamson DF, Kahn HS, Byers T. The 10-y incidence of obesity and major weight gain in black and white US women aged 30-55 y. Am J Clin Nutr. 1991;53(suppl 6):1515S-1518S.
4. Williamson DF. Descriptive epidemiology of body weight and weight change in U.S. adults. Ann Intern Med. 1993;119:646-649.
5. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119:655-660.
6. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension: the Framingham Study. Ann Intern Med. 1967;67:48-59.
7. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA. 1978; 240:1607-1610.
8. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
9. Garrison RJ, Kannel WB, Stokes JD, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987; 16:235-251.
10. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. Am J Epidemiol. 1997;145:614-619.
11. Garrison RJ, Higgins MW, Kannel WB. Obesity and coronary heart disease. Curr Opin Lipidol. 1996;7:199-202.
12. Rexrode KM, Hennekens CH, Willett WC, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA. 1997;277:1539-1545.
13. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998;128:81-88.
14. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women: risk within the 'normal' weight range. JAMA. 1995; 273:461-465.
15. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
16. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National High Blood Pressure Education Program, National Institutes of Health; 1997. Publication NIH 98-4080.
17. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.
18. Luscombe GP, Slater NA, Lyons MB, Wynne RD, Scheinbaum ML, Buckett WR. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCI. Psychopharmacology (Berl). 1990;100:345-349.
19. Gundlah C, Martin KF, Heal DJ, Auerbacn SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther. 1997;283:581-591.
20. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol. 1997;121:1613-1618.
21. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res. 1998;6:1-11.
22. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord. 1999;23:1009-1015.
23. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23:1016-1024.
24. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 1989;28:129-134.
25. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991;50:330-337.
26. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263-270.
27. Lean ME. Sibutramine - a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997;21(suppl1):S30-S36.
28. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord. 1998;22:32-38.
29. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res. 1998;6:115-121.
30. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198.
31. Apfelbaum MD, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179-184.
32. Bach DS, Rissanen AM, Mendel CM, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7:363-369.
33. Kolotkin RL, Head S, Hamilton M, Tse CK. Assessing impact of weight on quality of life. Obes Res. 1995;3:49-56.
34. Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 1989;149: 780-788.
35. Kumanyika SK. The association between obesity and hypertension in blacks. Clin Cardiol. 1989;12(suppl 4):IV72-IV77.
36. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is severe hypertension more common? Ann Epidemiol. 1996;6:173-180.
37. Kannel WB, Cupples LA, Ramaswami R, Stokes JD, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol. 1991;44:183-190.
38. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994;17:961-969.
39. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res. 1998;6(suppl 1):8S-17S.
40. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-1848.
41. Atkinson RL. Proposed standards for judging the success of the treatment of obesity. Ann Intern Med. 1993;119:677-680.
42. French SA, Jeffery RW, Folsom AR, McGovern P, Williamson DF. Weight loss maintenance in young adulthood: prevalence and correlations with health behavior and disease in a population-based sample of women aged 55-69 years. Int J Obes Relat Metab Disord. 1996;20:303-310.
43. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol. 1998;14(suppl B):14B-17B.
44. Ballantyne CM. Current thinking in lipid lowering. Am J Med. 1998;104:33S-41S.
45. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
46. Lamarche B, Lewis GF. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol. Can J Cardiol. 1998;14: 841-851.
47. Goldman L. Cholesterol reduction. In: Manson J, Ridker P, Gaziano J, Hennekens C, eds. Prevention of Myocardial Infarction. New York, NY: Oxford University Press; 1996:130-153.
48. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST, for The Normative Aging Study. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. Am J Epidemiol. 1995;142:288-294.
49. Pontiroli AE, Pacchioni M, Camisasca R, Lattanzio R. Markers of insulin resistance are associated with cardiovascular morbidity and predict overall mortality in long-standing non-insulin-dependent diabetes mellitus. Acta Diabetol. 1998; 35:52-56.
50. Fujioka K, Weinstein SP, Rowe E, McMahon FG. Sibutramine enhances weight loss in obese hypertensive patients taking angiotensin-converting enzyme (ACE) inhibitors [abstract]. Int J Obes Relat Metab Disord. 1998;22(suppl3):S65.
51. Liebowitz MT, Weinstein SP, McMahon FG. Sibutramine induces weight loss but not BP increase in obese hypertensive patients taking beta-blockers [abstract]. Am J Hypertens. 1998;11:107A.
52. Lackland DT, Keil JE, Gazes PC, Hames CG, Tyroler HA. Outcomes of black and white hypertensive individuals after 30 years of follow-up. Clin Exp Hypertens. 1995;17:1091-1105.
53. Saunders E. Hypertension in minorities: blacks. Am J Hypertens. 1995;8(12, pt 2):115s-119s.
54. Lackland DT, Keil JE. Epidemiology of hypertension in African Americans. Semin Nephrol. 1996;16:63-70.
55. Onwuanyi A, Hodges D, Avancha A, et al. Hypertensive vascular disease as a cause of death in blacks versus whites: autopsy findings in 587 adults. Hypertension. 1998;31:1070-1076.
56. Johnson F, Velagapudi R, Moult J, Faulkner R. An evaluation of long-term pharmacokinetic data following daily doses of 20 mg sibutramine (MERIDIA) and an ACE inhibitor in hypertensive obese patients [abstract]. J Clin Pharmacol. 1998; 21(suppl):S22.